ArticleMicrobiologyOpen2026
Exploring the Antimicrobial Potential of Vanadium-Based MXenes for Biomedical Applications.
Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Antimicrobial Potential of Vanadium-Based MXenes for Biomedical Applications.MicrobiologyOpen · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
MXenes, a family of two-dimensional transition metal carbides, carbonitrides and nitrides, have emerged as highly interesting antimicrobial nanomaterials. While mostly Ti-based MXenes have been explored in this field, our work aims at characterizing and investigating the antibacterial and biocompatibility profiles of two vanadium-based MXenes (V₂CTₓ and V₄C₃Tₓ) against Escherichia coli and Staphylococcus aureus, two clinically relevant pathobionts. First, the as-synthesized nanomaterials were chemically and structurally characterized to confirm their morphology and structural integrity. After setting up two distinct experimental models (static and dynamic), the antibacterial activity was evaluated by colony-forming units (CFUs) counting and scansion electron microscopy (SEM). Cellular cytotoxicity was assessed by lactate dehydrogenase (LDH) release and crystal violet characterization (CV). To further evaluate the MXenes' properties, the antimicrobial activity was tested in in-vitro infection models using both epithelial (Caco-2) and macrophage (J774) cells measuring CFUs. To assess the oxidative stress contributing to MXenes' antibacterial activity, reactive oxygen species (ROS) production was valued in infected cells after treatment. V₂CTₓ and V₄C₃Tₓ showed an antibacterial activity concentration and condition dependent. The dynamic incubation improved the bacterial reduction, supporting a "nano-knife" mechanism linked to the physical disruption of the membrane. Finally, V₂CTₓ and V₄C₃Tₓ significantly reduced the intracellular bacterial burden in infected Caco-2 epithelial cells in comparison with macrophages. Importantly, MXenes' treatment did not result in marked ROS stimulation, suggesting that their antibacterial activity mainly arose from physical interactions. Our findings highlight that vanadium-based MXenes have good biocompatibility and are moderately effective antimicrobial nanomaterials, emphasizing the need to use commonly recognized and standardized experimental models to elucidate their potential antimicrobial applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.